(Q35080058)

6 August 2017

1 reference

title

Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion (English)

1 reference

6 August 2017

1 reference

Lindberg P

1

1 reference

6 August 2017

Keeling D

2

1 reference

6 August 2017

Fryklund J

3

1 reference

6 August 2017

Andersson T

4

1 reference

6 August 2017

Lundborg P

5

1 reference

6 August 2017

Carlsson E

6

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Alimentary Pharmacology & Therapeutics

6 August 2017

1 reference

6 August 2017

17

1 reference

6 August 2017

4

1 reference

6 August 2017

481-488

1 reference

Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole

6 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

The physiological consequences of glutathione variations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01481.X

10.1046/J.1365-2036.2003.01481.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference